Harnessing stereotactic precision in the fight against primary kidney cancer: time for a randomised trial?
Mené sur 70 patients atteints d'un cancer à cellules rénales et inopérable (âge médian : 77 ans ; durée médiane de suivi : 43 mois ; 70 % d'hommes), cet essai international de phase II évalue l'efficacité, du point de vue du taux de contrôle local, d'une radiothérapie stéréotaxique d'ablation
Stereotactic ablative body radiotherapy (SABR) is a novel non-invasive definitive treatment option for primary renal cell carcinoma whereby ablative doses of radiation are delivered across one to five sessions using advanced technology. Although SABR is an attractive option for non-surgical candidates due to the mounting prospective evidence that is lacking for other ablative techniques, it begs the question of why SABR would not perform equally well on surgical candidates.
The Lancet Oncology 2024